AnaptysBio (ANAB) PT Raised to $70 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ANAB Hot Sheet
Price: $47.73 +1.75%
Rating Summary:
13 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
13 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Wedbush analyst David Nierengarten raised the price target on AnaptysBio (NASDAQ: ANAB) to $70.00 (from $45.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Citi Upgrades Ferrovial SA (FER:SM) (FRRVF) to Buy
- Beam Therapeutics Inc (BEAM) PT Raised to $49 at Jefferies
- COPT Defense Properties (CDP) PT Lowered to $36 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
